Zura Bio Limited (ZURA)
| Market Cap | 387.23M +55.1% |
| Revenue (ttm) | n/a |
| Net Income | -122.23M |
| EPS | -1.06 |
| Shares Out | 96.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,950,383 |
| Open | 4.120 |
| Previous Close | 3.990 |
| Day's Range | 3.832 - 4.200 |
| 52-Week Range | 3.250 - 7.440 |
| Beta | 0.01 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+372.64%) |
| Earnings Date | Oct 27, 2026 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ZURA stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 372.64% from the latest price.
News
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improv...
Zura Bio files $700M mixed securities shelf
17:17 EDT Zura Bio (ZURA) files $700M mixed securities shelf
Wedbush would be ‘aggressive buyer’ of Zura Bio ahead of key Q4 catalyst
Wedbush would be an aggressive buyer while Zura Bio (ZURA) remains below $4/share. The firm sees favorable risk/reward on the Q4 TibuSHIELD readout due to downside protection at about $3/share…
Zura Bio Registration statement: Registration filing
Zura Bio filed a registration statement on October 27, 2026, providing details about a securities offering with the SEC.
Zura Bio reports Q3 EPS (20c), consensus (21c)
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to…
Zura Bio sees cash runway through at least the end of 2028
As of September 30, 2026, Zura had cash and cash equivalents of $187.7 million. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through…
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio Quarterly report: Q3 2026
Zura Bio has published its Q3 2026 quarterly earnings report on October 27, 2026.
Zura Bio Earnings release: Q3 2026
Zura Bio released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Zura Bio management to meet virtually with Oppenheimer
Virtual Meeting to be held on October 12-13 hosted by Oppenheimer.
Zura Bio management to meet virtually with Piper Sandler
Virtual Meeting to be held on October 5 hosted by Piper Sandler.
Zura Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Upcoming data from a large phase II trial of a bispecific antibody in hidradenitis suppurativa could set a new efficacy benchmark by targeting both IL-17 and BAFF pathways. Additional trials in systemic sclerosis and polymyalgia rheumatica are underway, with a robust pipeline and strategic focus on high unmet needs.
Zura Bio management to meet with Piper Sandler
Investor Cocktail Reception to be held on September 9 hosted by Piper Sandler.
Zura Bio to Participate in the Cantor Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio price target raised to $20 from $15 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Zura Bio (ZURA) to $20 from $15 and keeps a Buy rating on the shares after the company reported Q2…
Zura Bio price target raised to $22 from $15 at Wedbush
Wedbush raised the firm’s price target on Zura Bio (ZURA) to $22 from $15 and keeps an Outperform rating on the shares. The firm notes the company reported earnings and…
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Zura Bio reports Q2 EPS (21c), consensus (19c)
“The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now complete in both TibuSHIELD and TibuSURE-each exceeding its initial enrollment target-underscori...
Zura Bio sees cash runway through the end of 2028
As of June 30, 2026, Zura had cash and cash equivalents of $205.1M. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at…
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio Quarterly report: Q2 2026
Zura Bio has published its Q2 2026 quarterly earnings report on August 11, 2026.
Zura Bio Earnings release: Q2 2026
Zura Bio released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Zura Bio initiated with an Outperform at William Blair
William Blair initiated coverage of Zura Bio (ZURA) with an Outperform rating. The firm sees potential for the dual mechanism of action of tibulizumab to drive “differentiated efficacy” in two…
Zura Bio Slides: Corporate presentation
Zura Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.